After pausing work on a rare cancer asset, Relay Therapeutics is passing the baton to Elevar Therapeutics. The two have signed a deal worth up to $500 million biobucks that gives Elevar licensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback